Showing 1 - 20 results of 121 for search '(( ct ((largest decrease) OR (marked decrease)) ) OR ( 500 ((mg decrease) OR (nn decrease)) ))', query time: 0.51s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Raw Data. by Hongfei Liu (1396348)

    Published 2025
    “…Ninety-six 12-week-old minks were randomly assigned to six groups (0, 100, 200, 300, 400, or 500mg/kg COS), with 8 replicates per treatment and 2 minks per replicate, for an 8-week trial. …”
  10. 10

    Loxoprofen and SB225002 administration decreased sound stress exposure-induced hyperalgesia. by Satoka Kasai (3861115)

    Published 2025
    “…Mice treated with loxoprofen (500mg/kg) or SB225002 (3 mg/kg) showed significantly decreased response times to the filament compared to Stress + saline group (Stress + loxoprofen (500mg/kg), 30 min after administration, **<i>P</i> < 0.01, 60 min after administration, ***<i>P</i><i> <i><</i> </i>0.001; Stress + SB225002 (3 mg/kg), 60 min after administration, *<i>P</i> < 0.05). 2-way ANOVA <i>post-hoc</i> Bonferroni test. …”
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf by Hua Wei (60877)

    Published 2025
    “…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …”
  18. 18
  19. 19

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  20. 20

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”